Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01579812 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients
A Phase 2 study of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT01579812 is a Phase 2 study of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 90 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01579812, a Phase 2 study of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to determine if metformin administered in combination with chemotherapy to women with advanced ovarian, primary peritoneal or fallopian tube cancer will improve recurrence-free survival at 18 months compared to controls.
Conditions Studied
Interventions
- DRUG Metformin
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2011-10 |
| Est. Completion | 2017-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01579812
The ClinicalTrials.gov registry entry for NCT01579812 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian, Fallopian Tube, and Primary Peritoneal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Metformin is the first listed.
NCT01579812 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT01579812 about?
NCT01579812 is a clinical study titled "Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients". The primary objective of this study is to determine if metformin administered in combination with chemotherapy to women with advanced ovarian, primary peritoneal or fallopian tube cancer will improve recurrence-free survival at 18 months compared to controls.
What is the current status of trial NCT01579812?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2011-10. Estimated completion is 2017-07.
What conditions does trial NCT01579812 study?
This clinical trial studies the following conditions: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
What interventions are being tested in trial NCT01579812?
The interventions under investigation include: Metformin (DRUG).
Who is sponsoring clinical trial NCT01579812?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01579812 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.